Bactericidal synergy of lysostaphin in combination with antimicrobial peptides

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 30, Issue 8, 2011, Pages 1015-1021

  Desbois, A P ^a   Coote, P J ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; COLISTIN; DAPTOMYCIN; DERMASEPTIN S3; GOMESIN; LACTOFERRIN; LYSOSTAPHIN; MAGAININ 2; NIGROCIN OG13; NISIN; ODORRANAIN G1; PEPTIDE 6752; PEPTIDE GS14K4; PEPTIDE KR 20; PEPTIDE MUC7 12MER; PEXIGANAN ACETATE; POLYMYXIN B; POLYPEPTIDE ANTIBIOTIC AGENT; RANALEXIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERIAL VIABILITY; BACTERICIDAL ACTIVITY; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; HEMOLYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DRUG SYNERGISM; HUMANS; LACTOFERRIN; LIPOPEPTIDES; LYSOSTAPHIN; MICROBIAL VIABILITY; NISIN; STAPHYLOCOCCUS;

EID: 80051546323     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-011-1188-z     Document Type: Article

References (37)

1. CA Schindler VT Schuhardt 1964 Lysostaphin: a new bacteriolytic agent for the Staphylococcus Proc Natl Acad Sci 51 414 421 14171453 10.1073/pnas.51.3.414 1:STN:280:DyaF2c7ivFCgsQ%3D%3D
2. RR Martin A White 1967 The selective activity of lysostaphin in vivo J Lab Clin Med 70 1 8 4961156 1:CAS:528:DyaF2sXksFaltLk%3D
3. JK Kumar 2008 Lysostaphin: an antistaphylococcal agent Appl Microbiol Biotechnol 80 555 561 18607587 10.1007/s00253-008-1579-y 1:CAS:528: DC%2BD1cXhtVKisLvL
4. I Mierau P Leij I van Swam B Blommestein E Floris J Mond EJ Smid 2005 Industrial-scale production and purification of a heterologous protein in Lactococcus lactis using the nisin-controlled gene expression system NICE: the case of lysostaphin Microb Cell Fact 4 15 15921518 10.1186/1475-2859-4-15 (Pubitemid 41460821)
5. R Sharma PR Sharma ML Choudhary A Pande GS Khatri 2006 Cytoplasmic expression of mature glycylglycine endopeptidase lysostaphin with an amino terminal hexa-histidine in a soluble and catalytically active form in Escherichia coli Protein Expr Purif 45 206 215 16181789 10.1016/j.pep.2005.07. 025 1:CAS:528:DC%2BD2MXhtlWqtLfN (Pubitemid 41773328)
6. P Szweda R Kotłowski J Kur 2005 New effective sources of the Staphylococcus simulans lysostaphin J Biotechnol 117 203 213 15823409 10.1016/j.jbiotec.2005.01.012 1:CAS:528:DC%2BD2MXivFKhtLk%3D (Pubitemid 40488709)
7. JF Kokai-Kun T Chanturiya JJ Mond 2007 Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model J Antimicrob Chemother 60 1051 1059 17848374 10.1093/jac/dkm347 1:CAS:528:DC%2BD2sXht1Sht77F (Pubitemid 47617753)
8. KL LaPlante 2007 In vitro activity of lysostaphin, mupirocin, and tea tree oil against clinical methicillin-resistant Staphylococcus aureus Diagn Microbiol Infect Dis 57 413 418 17141452 10.1016/j.diagmicrobio.2006.09.007 1:CAS:528:DC%2BD2sXjslGksL8%3D (Pubitemid 46498649)
9. FX Placencia L Kong LE Weisman 2009 Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: Lysostaphin versus vancomycin Pediatr Res 65 420 424 19127212 10.1203/PDR.0b013e3181994a53 1:CAS:528: DC%2BD1MXjt1SntLo%3D
10. AP Desbois CG Gemmell PJ Coote 2010 In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections Int J Antimicrob Agents 35 559 565 20206480 10.1016/j.ijantimicag.2010.01.016 1:CAS:528:DC%2BC3cXkvFOjtbc%3D
11. RC Pangule SJ Brooks CZ Dinu SS Bale SL Salmon G Zhu DW Metzger RS Kane JS Dordick 2010 Antistaphylococcal nanocomposite films based on enzyme-nanotube conjugates ACS Nano 4 3993 4000 20604574 10.1021/nn100932t 1:CAS:528: DC%2BC3cXosVOqt74%3D
12. S Boyle-Vavra RB Carey RS Daum 2001 Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate J Antimicrob Chemother 48 617 625 11679550 10.1093/jac/48.5.617 1:CAS:528:DC%2BD3MXovVykurY%3D (Pubitemid 33100307)
13. MW Climo K Ehlert GL Archer 2001 Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 45 1431 1437 11302806 10.1128/AAC.45.5.1431-1437.2001 1:CAS:528:DC%2BD3MXjtF2gsr4%3D (Pubitemid 32374113)
14. A Gründling DM Missiakas O Schneewind 2006 Staphylococcus aureus mutants with increased lysostaphin resistance J Bacteriol 188 6286 6297 16923896 10.1128/JB.00457-06 (Pubitemid 44448571)
15. J Polak PD Latta P Blackburn 1993 In vitro activity of recombinant lysostaphin-antibiotic combinations toward methicillin-resistant Staphylococcus aureus Diagn Microbiol Infect Dis 17 265 270 8112040 10.1016/0732-8893(93)90034- 5 1:CAS:528:DyaK2cXktlSqsLo%3D (Pubitemid 24028464)
16. MW Climo RL Patron BP Goldstein GL Archer 1998 Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis Antimicrob Agents Chemother 42 1355 1360 9624475 1:STN:280:DyaK1c3oslGksw%3D%3D (Pubitemid 28257631)
17. N Kiri G Archer MW Climo 2002 Combinations of lysostaphin with β-lactams are synergistic against oxacillin-resistant Staphylococcus epidermidis Antimicrob Agents Chemother 46 2017 2020 12019130 10.1128/AAC.46.6.2017-2020.2002 1:CAS:528:DC%2BD38XktFCmt7s%3D (Pubitemid 34535236)
18. E Walencka B Sadowska S Różalska W Hryniewicz B Różalska 2006 Staphylococcus aureus biofilm as a target for single or repeated doses of oxacillin, vancomycin, linezolid and/or lysostaphin Folia Microbiol 51 381 386 10.1007/BF02931580 1:CAS:528:DC%2BD28Xht1yjsbvK (Pubitemid 44807741)
19. S Graham PJ Coote 2007 Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin J Antimicrob Chemother 59 759 762 17324959 10.1093/jac/dkl539 1:CAS:528:DC%2BD2sXltVKgsbc%3D (Pubitemid 47073414)
20. JF Kokai-Kun T Chanturiya JJ Mond 2009 Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice J Antimicrob Chemother 64 94 100 19398455 10.1093/jac/dkp145 1:CAS:528:DC%2BD1MXntlGgsb8%3D
21. G Cisani PE Varaldo G Grazi O Soro 1982 High-level potentiation of lysostaphin anti-staphylococcal activity by lysozyme Antimicrob Agents Chemother 21 531 535 7081976 1:CAS:528:DyaL38XhvFKnsbk%3D (Pubitemid 12070516)
22. SC Becker J Foster-Frey DM Donovan 2008 The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA FEMS Microbiol Lett 287 185 191 18721148 10.1111/j.1574-6968.2008.01308.x 1:CAS:528:DC%2BD1cXht1ymtrvJ
23. Walsh SM, Shah AG, Mond JJ (2004) Topical anti-infective formulations. US Patent publication no. US 2004/0192581 A1
24. REW Hancock 1997 Peptide antibiotics Lancet 349 418 422 9033483 10.1016/S0140-6736(97)80051-7 1:CAS:528:DyaK2sXhvVamur0%3D (Pubitemid 27077684)
25. MR Yeaman NY Yount 2003 Mechanisms of antimicrobial peptide action and resistance Pharmacol Rev 55 27 55 12615953 10.1124/pr.55.1.2 1:CAS:528:DC%2BD3sXisVKgsLg%3D (Pubitemid 36268398)
26. AK Marr WJ Gooderham REW Hancock 2006 Antibacterial peptides for therapeutic use: obstacles and realistic outlook Curr Opin Pharmacol 6 468 472 16890021 10.1016/j.coph.2006.04.006 1:CAS:528:DC%2BD28XpsVWrs7s%3D (Pubitemid 44340665)
27. GG Perron M Zasloff G Bell 2006 Experimental evolution of resistance to an antimicrobial peptide Proc R Soc B 273 251 256 16555795 10.1098/rspb.2005. 3301 1:CAS:528:DC%2BD28XjvFeqtL8%3D (Pubitemid 46768100)
28. AP Desbois S Lang CG Gemmell PJ Coote 2010 Surface disinfection properties of the combination of an antimicrobial peptide, ranalexin, with an endopeptidase, lysostaphin, against methicillin-resistant Staphylococcus aureus (MRSA) J Appl Microbiol 108 723 730 19709343 10.1111/j.1365-2672.2009.04472.x 1:CAS:528:DC%2BC3cXitF2gsb4%3D
29. PE Mead JW Tweedie 1990 cDNA and protein sequence of bovine lactoferrin Nucl Acids Res 18 7167 2263492 10.1093/nar/18.23.7167 1:CAS:528: DyaK3MXktVaisLs%3D
30. RL White DS Burgess M Mandura JA Bosso 1996 Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test Antimicrob Agents Chemother 40 1914 1918 8843303 1:CAS:528:DyaK28Xks12qurc%3D (Pubitemid 26277815)
31. G Francius O Domenech MP Mingeot-Leclercq YF Dufrêne 2008 Direct observation of Staphylococcus aureus cell wall digestion by lysostaphin J Bacteriol 190 7904 7909 18835985 10.1128/JB.01116-08 1:CAS:528: DC%2BD1cXhsV2lsLrO
32. Scholar EM, Pratt WB (2000) Antibiotics that affect membrane permeability. In: Scholar EM, Pratt WB (eds) The antimicrobial drugs, 2nd edn. Oxford University Press, New York, pp 234-241
33. B Bechinger K Lohner 2006 Detergent-like actions of linear amphipathic cationic antimicrobial peptides Biochim Biophys Acta 1758 1529 1539 16928357 10.1016/j.bbamem.2006.07.001 1:CAS:528:DC%2BD28XhtVamsr7K (Pubitemid 44436087)
34. LGM Moraes M Fázio RFF Vieira CR Nakaie MTM Miranda S Schreier S Daffre A Miranda 2007 Conformational and functional studies of gomesin analogues by CD, EPR and fluorescence spectroscopies Biochim Biophys Acta 1768 52 58 17027634 10.1016/j.bbamem.2006.08.016 1:CAS:528:DC%2BD28Xhtlaltb3O (Pubitemid 44920308)
35. JM Willey WA van der Donk 2007 Lantibiotics: peptides of diverse structure and function Annu Rev Microbiol 61 477 501 17506681 10.1146/annurev.micro.61.080706.093501 1:CAS:528:DC%2BD2sXhtlart77I (Pubitemid 350058218)
36. L Gottler A Ramamoorthy 2009 Membrane orientation, mechanism, and function of pexiganan-a highly potent antimicrobial peptide designed from magainin Biochim Biophys Acta 1788 1680 1686 19010301 10.1016/j.bbamem.2008.10. 009 1:CAS:528:DC%2BD1MXnt1Ghtbo%3D
37. L Robbel MA Marahiel 2010 Daptomycin, a bacterial lipopeptide synthesized by a nonribosomal machinery J Biol Chem 285 27501 27508 20522545 10.1074/jbc.R110.128181 1:CAS:528:DC%2BC3cXhtVOns7fL